Zoom Video Communications to Release Financial Results for the First Quarter of Fiscal Year 2022

SAN JOSE, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), a leading provider of frictionless enterprise video communications, today announced it will release its financial results for the first quarter of fiscal year 2022 on Tuesday, June 1, 2021, after the market closes.

A live Zoom Video Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom's investor relations website at https://investors.zoom.us. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Public Relations
Colleen Rodriguez
Global PR Lead for Zoom

Investor Relations
Tom McCallum
Head of Investor Relations for Zoom

GLOBENEWSWIRE (Distribution ID 8228317)

iGrafx Announces Appointment of Andrew McFarland to Chief Executive Officer

PORTLAND, Ore., May 03, 2021 (GLOBE NEWSWIRE) — iGrafx, a world leader in digital business transformation, announced the appointment of Andrew McFarland to Chief Executive Officer, effective immediately.

Andrew joined iGrafx in October 2020 as Chief Customer Officer, bringing more than 25 years' experience in executive leadership. "Andy is a proven leader who develops employees, drives vision, consistently exceeds goals" stated Joel Trammel, chairman of iGrafx and managing partner of Lone Rock Technology Group.

As a trusted advisor to investors and executive teams alike, Andrew will help iGrafx continue to develop innovative business strategies and client–focused solutions that enable organizations improve their processes, drive growth, and transform their business.

About iGrafx

iGrafx believes that process is at the center of everything, and helps the largest, most complex enterprises around the world convert their business processes into a portfolio of valuable assets. The iGrafx Business Transformation Platform is the world's most comprehensive, supporting RPA and workflow automation, customer journey, governance, risk, compliance, and more, as well as SaaS and private cloud deployment. It is also the most scalable, currently accommodating the largest, global enterprise requirements. iGrafx possesses and shares 400+ years of process passion.

For more information, please visit: https://www.igrafx.com


For more information, press only:

2021 iGrafx, LLC. All rights reserved. iGrafx and the iGrafx logo are trademarks or registered trademarks of iGrafx, LLC.


GLOBENEWSWIRE (Distribution ID 8228128)

BANDroyalty.com Set to Revolutionize Music Worldwide May 5 with Release of BAND NFTs on OpenSea.io

SINGAPORE, May 03, 2021 (GLOBE NEWSWIRE) — via InvestorWire "" BAND Royalty ("BAND" or the "Company"), operated by Singapore–based LIBERTY IS PTE LTD, launches its first music/art collectibles, the BAND NFTs Series 1, on May 5, 2021. These NFTs have been commissioned by phenomenal artists to celebrate the world's incredible diversity, inclusivity and varieties of music. Even still, these BAND NFT collectibles have a twist. Unlike NBA Topshots or CryptoKitties, owning just one of the 3,000 limited–edition BAND NFTs provides access to the BAND Music NFT ecosystem and the opportunity to share in BAND's performance royalty music catalog. Over 50 top artists are represented, including the amazing Beyonce, Jay–Z, Justin Timberlake, Cher, will.i.am, Timbaland, Missy Elliot and Rihanna. BAND Royalty is making this set a first among NFTs, creating a unique music/art NFT Collectible that music lovers worldwide are sure to treasure.

NFTs, or non–fungible tokens, represent uniquely cryptographically secured works such as music, artwork, videos and other digital files stored on the blockchain.

The BAND NFT Series 1 launches Wednesday, May 5, and is limited to only 3,000. These beautifully designed NFTs stand out through stunning artwork and will eventually allow holders to stake their BAND NFTs into various BAND royalty pools of songs and artists.

BAND Royalty founders Barnaby Andersun and Noble Drakoln, experts in the fields of blockchain and music royalty investing and co–hosts of the CryptoTenX Podcast, have outlined a robust and ambitious roadmap of releases for BAND Royalty in 2021. Starting with this NFT Series 1, BAND Royalty will eventually introduce Band TOKENS and launch a new platform for musicians and fans to interact through NFTs.

Band Royalty plans to grow its catalog of famous and income driven royalty rights through the release of 12,000 total capped unique NFT tokens across four different NFT series in 2021, similar to the limited collectible nature of Crypto Punks and Hashmasks. Funds generated will be reinvested to expand BAND Royalty's music royalty library.

Securing one of the converted and rare 3,000 Series 1 collectible BAND NFT 3D animated music inspired pieces of digital art is simple. On launch day, this limited edition will be available on a first–come, first–serve basis through an offering on OpenSea.io.

To ensure success, holders need at least 1 Ethereum available in an ETH wallet before visiting OpenSea.io – the largest Ethereum NFT marketplace in the world. Once there, review the beautiful selection of BAND NFT art and make a selection. The lower the number of the BAND NFT, the more rare it is; bringing with it increased collectability and functional access across the BAND music ecosystem.

To learn more, you are invited to the BAND community: https://t.me/bandroyalty

About BAND Royalty

BAND Royalty lets music lovers and fans take their enjoyment of music to the next level by offering blockchain–secured BAND NFTs that enable holders to earn crypto from some of the world's most popular songs. This unique opportunity allows individuals to share in income streams each time a song in the BAND music catalog is performed. The name BAND is derived from the initials of its co–founders, blockchain experts Barnaby Andersun (BA) + Noble Drakoln (ND). To learn more about BAND Royalty and to sign up for NFT collection release drops, visit www.bandroyalty.com.

Contact: info@bandroyalty.com

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
310.299.1717 Office

GLOBENEWSWIRE (Distribution ID 8227578)

Zenas BioPharma Announces New Executive Leadership Appointments

Hua Mu, MD, Ph.D. appointed President, CEO and Acting CMO

Joe Farmer appointed CBO

HONG KONG and BOSTON, May 03, 2021 (GLOBE NEWSWIRE) — Zenas BioPharma ("Zenas"), a cross–border (China–USA based) biopharmaceutical company committed to the development and delivery of immune–based therapies, today announced the appointment of Hua Mu, MD, Ph.D. as President and Chief Executive Officer and Acting Chief Medical Officer and Joe Farmer as Chief Business and Administrative Officer.

"We are delighted to have Hua join the Zenas executive leadership team," said Lonnie Moulder, Founder and Executive Chairman. "His extensive experience, including building and leading R&D organizations in China, and his track record of successful development and approval of new drugs in the US and China will be critical as Zenas builds a global organization and advances its innovative pipeline of immune–based therapies."

Dr. Mu joins Zenas after co–founding Overland Pharmaceuticals and serving as Interim Chief Executive Officer and Chief Medical Officer, while also serving as Venture Partner at Hillhouse Capital. Prior to Overland, Dr. Mu served as Chief Scientific Officer and President of R&D and later Chief Medical Officer of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was Senior Vice President and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was Executive Vice President and Chief Medical Officer at Hutchison MediPharma in China. He previously held clinical development executive roles at several global pharmaceutical companies in the US, including Biogen and Genentech.

Dr. Mu received his Ph.D. from the University of California at Berkeley and completed his post–doctorate training at University of California at San Francisco School of Medicine and University of Washington School of Medicine. He received his MD degree from West China University of Medical Sciences.

"Zenas is an innovative biopharmaceutical company uniquely positioned at the nexus of drug development and product flow between China and the West, with an exceptional management team, a world class investor base, and an impressive pipeline of differentiated programs," said Dr. Mu. “I am thrilled to work with the entire Zenas team and network of partners to achieve our mission to transform the lives of patients with unmet medical needs by bringing best–in–class immune–based therapies to the world."

Zenas also announced the appointment of Joe Farmer as Chief Business and Administrative Officer. Mr. Farmer is an accomplished biopharma executive with approximately 25 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, Mr. Farmer served as Chief Operating Officer at Xilio Therapeutics.

Prior to Xilio, Mr. Farmer was the General Counsel and Corporate Secretary at TESARO, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team through its acquisition by GlaxoSmithKline in 2019. He previously served as Chief Corporate Counsel at Cubist Pharmaceuticals through its acquisition by Merck in 2015 and served at other publicly traded companies as General Counsel and Chief Administrative Officer. Mr. Farmer began his career as a corporate attorney at Testa Hurwitz & Thibeault. He received his J.D. from Boston College Law School.

"With the appointments of Hua and Joe, Zenas has further strengthened its executive leadership team," said Lonnie Moulder. "Their respective expertise in building global organizations and executing corporate development strategy through all phases of drug development and commercialization will be invaluable as we continue to advance our global development programs and expand our novel pipeline."

About Zenas BioPharma

Zenas BioPharma is a cross–border (China–USA based) biopharmaceutical company committed to becoming a global leader in the development and delivery of immune–based therapies for patients in China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.


Investor Contact:

Zenas BioPharma

Media Contact:

Lauren Bartlett
Zenas BioPharma

GLOBENEWSWIRE (Distribution ID 8227397)